Jump to:
Mike Tentilucci joined Ropes & Gray's corporate department in 2021. Mike focuses his practice on representing public companies and investment banks in connection with capital markets transactions and compliance with securities laws and stock exchange rules and regulations, as well as mergers & acquisitions, other strategic transactions and general corporate governance matters.
Experience
Mike has represented:
- the lead underwriters in the $308 million initial public offering and follow-on equity offerings totaling $1.4 billion for Loar Holdings Inc.
- the lead underwriters in follow-on equity offerings totaling $1.1 billion for Madrigal Pharmaceuticals, Inc.
- TPG Capital, Leonard Green & Partners and Partners Group as selling shareholders of Life Time Fitness in secondary equity offerings totaling $1.6 billion.
- Zenas BioPharma, Inc. in its $120 million PIPE financing and $200 million at-the-market offering.
- Avista Healthcare Partners in its purchase of $130 million of convertible preferred stock of Organogenesis Holdings Inc.
- Sanofi in strategic investments in SAB Biotherapeutics and Immuneering.
- Novalis LifeSciences in its PIPE investment in Telesis Bio.
- Cyteir Therapeutics, Inc. in its $133.2 million initial public offering and disclosure and governance matters.
- the lead underwriters in the initial public offering of byNordic Acquisition Corporation.
- the lead underwriters in the initial public offering of CIIG Capital Partners II, Inc.
- the lead underwriters in the initial public offering of Tio Tech A.
- Novavax, Inc. in equity offerings and disclosure and governance matters.
- RVL Pharmaceuticals plc in equity offerings and disclosure and governance matters.
- Acceleron Pharma Inc. in its sale to Merck.
- Pfizer Inc. in its acquisition of Trillium Therapeutics.
- TransMedics Group, Inc. in its acquisition of organ support and heart preservation transport system assets from Bridge to Life Ltd.
- Arbor Biotechnologies in its $73.9 million Series C financing.
- an investment manager in the Series B financing for Breeze Aviation Group, Inc.